A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Public ClinicalTrials.gov record NCT00880217. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study of 3 Dosages of JNJ-31001074 in the Treatment of Adult Subjects With Attention-Deficit/Hyperactivity Disorder
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety/tolerability of 3 different dosages of JNJ-31001074 compared with placebo in adult patients with attention-deficit/hyperactivity disorder (ADHD).
Study identification
- NCT ID
- NCT00880217
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 430 participants
Conditions and interventions
Conditions
Interventions
- Atomoxetine 80 mg/d Drug
- Placebo Drug
- OROS methylphenidate HCl 54 mg/d Drug
- JNJ-31001074 3 mg/d Drug
- JNJ-31001074 1 mg/d Drug
- JNJ-31001074 10 mg/d Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2009
- Primary completion
- Dec 31, 2009
- Completion
- Dec 31, 2009
- Last update posted
- Mar 3, 2013
2009 – 2010
United States locations
- U.S. sites
- 35
- U.S. states
- 22
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Lafayette | California | — | — |
| Not listed | Los Alamitos | California | — | — |
| Not listed | Santa Ana | California | — | — |
| Not listed | Wildomar | California | — | — |
| Not listed | Bradenton | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | North Miami | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | South Miami | Florida | — | — |
| Not listed | St. Petersburg | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Boise | Idaho | — | — |
| Not listed | Eagle | Idaho | — | — |
| Not listed | Libertyville | Illinois | — | — |
| Not listed | Overland Park | Kansas | — | — |
| Not listed | Prairie Village | Kansas | — | — |
| Not listed | Rochester Hills | Michigan | — | — |
| Not listed | Saint Charles | Missouri | — | — |
| Not listed | Mount Kisco | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Dayton | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Eugene | Oregon | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Media | Pennsylvania | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Memphis | Tennessee | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Wharton | Texas | — | — |
| Not listed | Burlington | Vermont | — | — |
| Not listed | Herndon | Virginia | — | — |
| Not listed | Seattle | Washington | — | — |
| Not listed | Middleton | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00880217, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 3, 2013 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00880217 live on ClinicalTrials.gov.